Free Trial

Artivion (AORT) Stock Price, News & Analysis

Artivion logo
$24.68 -0.29 (-1.18%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Artivion Stock (NYSE:AORT)

Key Stats

Today's Range
$24.60
$25.02
50-Day Range
$23.46
$31.69
52-Week Range
$19.36
$32.33
Volume
62,285 shs
Average Volume
266,058 shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.40
Consensus Rating
Buy

Company Overview

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Remove Ads

Artivion Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

AORT MarketRank™: 

Artivion scored higher than 71% of companies evaluated by MarketBeat, and ranked 265th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Artivion has only been the subject of 2 research reports in the past 90 days.

  • Read more about Artivion's stock forecast and price target.
  • Earnings Growth

    Earnings for Artivion are expected to grow by 35.14% in the coming year, from $0.37 to $0.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Artivion is -1,232.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Artivion is -1,232.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Artivion has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Artivion's valuation and earnings.
  • Percentage of Shares Shorted

    9.72% of the float of Artivion has been sold short.
  • Short Interest Ratio / Days to Cover

    Artivion has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Artivion has recently decreased by 1.29%, indicating that investor sentiment is improving.
  • Dividend Yield

    Artivion does not currently pay a dividend.

  • Dividend Growth

    Artivion does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.72% of the float of Artivion has been sold short.
  • Short Interest Ratio / Days to Cover

    Artivion has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Artivion has recently decreased by 1.29%, indicating that investor sentiment is improving.
  • News Sentiment

    Artivion has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Artivion this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for AORT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,356,223.00 in company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of Artivion is held by insiders.

  • Percentage Held by Institutions

    86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Artivion's insider trading history.
Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

AORT Stock News Headlines

3 Under-$10 Stocks That Could Skyrocket
Looking for affordable stocks that could deliver big returns? Our latest report showcases 3 buy-rated stocks under $10 that analysts believe have major upside potential. Don’t miss out on these hidden opportunities that could boost your portfolio.
Artivion, Inc. (NYSE:AORT) CFO Sells $89,003.29 in Stock
Artivion price target lowered to $32 from $34 at Needham
Artivion price target lowered to $30 from $33 at Stifel
See More Headlines

AORT Stock Analysis - Frequently Asked Questions

Artivion's stock was trading at $28.59 at the start of the year. Since then, AORT stock has decreased by 13.9% and is now trading at $24.6250.
View the best growth stocks for 2025 here
.

Artivion, Inc. (NYSE:AORT) announced its quarterly earnings results on Monday, February, 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by $0.51. The firm had revenue of $97.31 million for the quarter, compared to analysts' expectations of $100.82 million. Artivion had a positive trailing twelve-month return on equity of 5.15% and a negative net margin of 0.22%.

Top institutional shareholders of Artivion include Vanguard Group Inc. (6.69%), Wellington Management Group LLP (3.96%), Wellington Management Group LLP (3.95%) and Dimensional Fund Advisors LP (3.51%). Insiders that own company stock include James P Mackin, David Ashley Lee, Jean F Holloway, Marshall S Stanton, Lance A Berry, Rochelle L Maney, Dennis B Maier, Matthew A Getz and Andrew M Green.
View institutional ownership trends
.

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
2/24/2025
Today
3/25/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NYSE:AORT
Employees
1,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.40
High Stock Price Target
$33.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+26.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
67.03
P/E Growth
N/A
Net Income
$-30,690,000.00
Pretax Margin
2.21%

Debt

Sales & Book Value

Annual Sales
$388.54 million
Cash Flow
$0.67 per share
Price / Cash Flow
36.78
Book Value
$6.87 per share
Price / Book
3.61

Miscellaneous

Free Float
38,524,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
1.79
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:AORT) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners